Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ACADIA PHARMACEUTICALS INC Director's Dealing 2013

Nov 1, 2013

31237_dirs_2013-11-01_7384629e-5adb-415c-883a-ba8636b11a0f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2013-11-01

Reporting Person: Hacksell Uli (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-11-01 Common Stock M 15000 $2 Acquired 15000 Direct
2013-11-01 Common Stock G 15000 Disposed 0 Direct
2013-11-01 Common Stock G 15000 Acquired 124049 Indirect
2013-11-01 Common Stock S 15000 $23.2425 Disposed 109049 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-11-01 Stock Option (right to buy) $2 M 15000 Disposed 2014-03-11 Common Stock (15000) Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2013.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.20 to $23.30 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.

F3: 25% of the shares subject to the stock option vested and became exercisable on March 12, 2005. The remaining shares vested in equal monthly installments over the following 3 years.